A novel hepatitis C vaccine has developed by French researchers, which may offer the first effective means to prevent infection that can cause chronic liver disease and live cancer. At present there is no vaccine available for hepatitis C, though some drug companies are developing curative vaccine for hepatitis C.
These therapeutic vaccines are designed to help patients those are already contaminated. The novel trail shot had been successfully tested on animals and has shown to trigger an extensive response from immune system protein known as neutralizing antibodies. These antibodies battled against manifold variants of the hepatitis C virus in trails.
This suggests that the new vaccine would be effective even after the virus mutates. The neutralizing of antibodies plays a crucial in most existing vaccines against other diseases, however harnessing them in hepatitis C has proved intangible previously. The latest work on remedial vaccines has focused on an additional immune system method known as T-cells.
According to an estimate the World Health Organization, nearly one hundred and seventy million people globally are chronically infected with hepatitis C virus and more than three million people die from hepatitis C-related liver diseases each year. Dissimilar to hepatitis B or A, the majority of people with hepatitis C develop chronic disease as their bodies are unable to get rid of the virus.
The condition is spread by exposure to infected blood. The mainstay of treatment for the condition has been interferon and ribavirin-based therapy, though recently Vertex and Merck have both launched promising new drugs. The trial vaccine uses virus-like particles, which resemble viruses but are non-infectious as they do not contain any viral genetic matter.
The details of new drug development were published in the journal Science Translational Medicine. The commercial rights to the new vaccine are held by French start-up Epixis. For a preventative vaccine, neutralizing antibodies are absolutely essential, and for a therapeutic product they would also be a big advantage, explained co-researcher David Klatzmann.